SCHEMBL8470834

SCHEMBL8470834

CCOC(=O)Nc1cccc(N2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 3/20 0.55
▸ VCP P55072 1/20 0.50
▸ DRD2 P14416 1/20 0.50
▸ ADRA1A P35348 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ NAMPT P43490 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ MAPT P10636 5/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 3/20 0.47
▸ HTT P42858 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ PARP14 Q460N5 1/20 0.47
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8471288 0.89 GPR119 (0.57) GPR119NAMPTALDH1A1MAPTMEN1
SCHEMBL13979397 0.88 GPR119 (0.61) GPR119NAMPTALDH1A1MAPTMEN1
SCHEMBL13853614 0.83 GPR119 (0.56) GPR119NAMPTALDH1A1MAPTMEN1
SCHEMBL21966981 0.83 GPR119 (0.60) GPR119NAMPTALDH1A1MAPTMEN1
SCHEMBL27118563 0.82 GPR119 (0.55) GPR119NAMPTALDH1A1MAPTMEN1
SCHEMBL8250825 0.82 L3MBTL1 (0.59) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL30063444 0.82 L3MBTL1 (0.59) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL674604 0.81 GPR119 (0.56) GPR119ALDH1A1MAPTMEN1KMT2A
SCHEMBL7364473 0.80 GPR119 (0.53) GPR119ALDH1A1MAPTMAPK1HTT
SCHEMBL29498206 0.80 GPR119 (0.57) GPR119NAMPTALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875617-B2 N-[4-(2-methoxyphenyl)piperazin-1-yl)butyl]-3,4-dihydro-6-fluoro-2-naphthamide for treating neuropsychological disorder selected from Parkinson's disease, schizophrenia and depression; partial agonists or antagonists of the dopamine D3 receptor INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2011-01-25 — — US disclosed
US-20090124630-A1 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-05-14 — — US disclosed
EP-1683790-A1 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2006-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124630-A1 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS DRD3, SLC6A3, DRD2 GPR119 190/4885VCP 2970/4885DRD2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback